Koers Oncology Pharma Inc. Other OTC
Aandelen
ONPH
US68235J2015
Farmaceutische producten
Omzet 2003 | 3,28 mln. 3,06 mln. | Omzet 2004 | 1,18 mln. 1,1 mln. | Marktkapitalisatie | 3,87K 3,61K |
---|---|---|---|---|---|
Nettowinst (verlies) 2003 | -1 mln. -934K | Nettowinst (verlies) 2004 | -1 mln. -934K | EV/omzet 2003 | - |
Nettoliquiditeiten 2003 | 1,35 mln. 1,26 mln. | Nettoschuld 2004 | 17K 15,88K | EV/omzet 2004 | - |
K/w-verhouding 2003 * |
-
| K/w-verhouding 2004 |
-
| Werknemers | - |
Dividendrendement 2003 * |
-
| Dividendrendement 2004 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
George Malesek
CEO | Chief Executive Officer | - | - |
James B. Smith
DFI | Director of Finance/CFO | - | 28-01-21 |
Charles Wagner
CHM | Chairman | - | 30-09-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Stefan Gruenwald
BRD | Director/Board Member | - | 08-10-19 |
Charles Wagner
CHM | Chairman | - | 30-09-14 |
Carlos Barnett
BRD | Director/Board Member | - | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+50,70% | 795 mld. | |
+41,96% | 627 mld. | |
-7,15% | 350 mld. | |
+18,77% | 328 mld. | |
+8,79% | 294 mld. | |
+18,02% | 245 mld. | |
+1,27% | 222 mld. | |
+11,95% | 215 mld. | |
+3,68% | 160 mld. |